Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Radiation therapy is one of the important tools in the fight against cancer. About 50% of all cancer patients receive radiation therapy. Few modalities have had the same lasting impact across such a broad range of tumor types. In central nervous system (CNS) oncology,...
There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...
A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...
Scientists have uncovered how plants produce mitraphylline, a rare natural compound with demonstrated anti cancer properties, shedding new light on the biological machinery behind one of nature’s most complex chemical products. By identifying the key enzymes involved...
Biotech is showing early signs of life after a prolonged funding winter, but for many early-stage companies, conditions remain unforgiving. Years of low valuations, high borrowing costs and regulatory uncertainty have reshaped investor behaviour, with capital scarce...
The life sciences sector sits at the intersection of discovery, technology and human impact. From developing new medicines and diagnostics to advancing environmental sustainability and digital health, careers in life sciences offer the chance to work on problems that...
For decades, obesity has been defined and diagnosed primarily using body mass index (BMI), a simple ratio of weight to height. While BMI has been widely adopted for its convenience and scalability, a growing body of research now suggests that it may be an incomplete...
Spinal cord injuries remain one of the most challenging conditions in modern medicine. Damage to the spinal cord often leads to permanent paralysis, loss of sensation, and a dramatic decline in quality of life. For decades, treatment options have been limited to...
Basecamp Research, a frontier AI lab harnessing evolution to design new medicines, today announced the first AI models capable of programmable gene insertion, offering a new way to replace faulty genes and reprogram cells for therapeutic use. Trained in collaboration...
Peptides are no longer confined to the margins of biomedical research. Once viewed primarily as niche tools for probing biological pathways or as incremental drug candidates, peptides and related biomolecules are now emerging as a central pillar of innovation across...
How Modular Hardware Is Breaking Decades of Vendor Lock-In There’s a running joke among biotech lab managers that goes something like this: You don’t buy a bioreactor. You buy a relationship. A very expensive, very locked-in relationship. It’s funny because it’s...
India is emerging as one of the most dynamic life sciences markets in the world. Long recognised for its strength in pharmaceuticals and generics, the country is now experiencing a broader life sciences boom that spans biotechnology, vaccines, medical devices,...
Swiss biotechnology company Windward Bio has entered into a significant licensing agreement with Chinese biotech Qyuns Therapeutics, securing rights outside China to a clinical stage immunology bispecific antibody known as WIN027, also referred to as QX027N. The...
Artificial intelligence is increasingly being judged on clinical progress and tangible outcomes, not just models and algorithms. Once a speculative concept, AI-driven drug discovery is now generating real-world data, advancing molecules into human studies, reshaping...
The landscape of global disease continues to evolve, shaped by demographic shifts, environmental pressures, and rapid advances in biomedical innovation. For life science professionals, understanding where the world’s highest-burden diseases stand today, and where...